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ABSTRACT 
Objective: To compare the efficacy and safety of oral Labetalol and Nifedipine in preeclampsia patients and to aid professionals in making 
appropriate therapeutic decisions in the management of preeclampsia. 
Methods: A Prospective observational study with the total of 152 pregnant women with preeclampsia is conducted in a Tertiary Care Hospital in 
India. Pregnant women with preeclampsia prescribed with either oral labetalol or oral nifedipine were selected. Main outcome measures include 
monitoring of adverse effects of labetalol and nifedipine and efficacy of both drugs. Blood pressures were measured every 4 hrs using 
sphygmomanometer and average of three consecutive readings is recorded. The two groups were followed until delivery and are interviewed for 
any adverse reactions. 
Results: The duration of days required for labetalol to normalize the high blood pressure is 5 days (5±2.63 d), and that of nifedipine is 7.5 days 
(7.5±3.83 d) with P value of 0.0015. Common adverse Drug reactions (ADR’s) of the both drugs are pedal edema (50%, 47.36%), headache (44.7%, 
26.31%), and orthostatic hypotension (9%, 7%) etc are compared. 
Conclusion: Oral Labetalol is more efficacious than Oral Nifedipine, with an exception of more adverse effects and high cost. 
Keywords: Preeclampsia, Safety, Efficacy, Labetalol, Nifedipine. 
 
INTRODUCTION 
Hypertensive disorders of pregnancy are an important cause of 
severe morbidity and mortality among both mother and fetus [1]. 
Pregnant women with hypertension have more chance to develop 
placental abruption, disseminated intravascular coagulation (DIC), 
cerebral hemorrhage, hepatic failure and acute renal failure [2]. 
Hypertensive disorders of pregnancy include Preeclampsia, 
Eclampsia, Chronic hypertension, gestational hypertension and 
preeclampsia superimposed on chronic hypertension [3, 4]. 
Among the pregnancy complicating hypertensive disorders, Pre-
eclampsia and Eclampsia are the major causes of maternal and 
perinatal mortality and morbidity [1]. 
Preeclampsia is defined as a systolic blood pressure ≥ 140 mmHg or 
diastolic blood pressure ≥ 90 mmHg on 2 occasions at least 4 h apart 
after 20 w gestation in women with a previously normal blood 
pressure or ≥160 mmHg systolic or ≥110 mmHg diastolic, confirmed 
within a short interval (minutes) to facilitate timely 
antihypertensive therapy and Proteinuria ≥ 300 mg/24 h  or a 
protein/creatinine ratio ≥ 0.3 mg/d l or a dipstick reading of ≥ 
1+reading [5]. 
Worldwide about 76,000 pregnant women die each year from 
preeclampsia and related hypertensive disorders. Fetal mortality 
rate is thought to be on the order of 5,00,000 per annum [6]. The 
prevalence of Preeclampsia in developing countries ranges from 
1.8% to 16.7% [7].The Recent United Kingdom (UK) guidelines from 
the National Institute of Health and Clinical Excellence (NICE) 
recommend oral Labetalol as the first line choice in the treatment of 
hypertension in pregnancy [8]. 
Novelity of the study 
Selection of antihypertensive agent is the major issue concerned 
with pre-eclampsia. National Institute of Health and Clinical 
Excellence Guidelines suggests that Labetalol, Nifedipine and 
Methyldopa are preferred choice of drugs. The use of anti-
hypertensive drugs in pregnancy is controversial as most 
antihypertensive agents used in pregnancy are designated as 
Category ‘C’ stating that human studies are lacking. Clinicians vary in 
their choice of treatment for hypertension in pregnancy and there is 
uncertainty regarding potential benefits and harms of using 
antihypertensive drugs in pregnancy.  
A meta-analysis study of Randomized controlled trials conducted for 
the assessment of efficacy, side effects and perinatal outcome of 
nifedipine compared with other antihypertensives for treating 
severe preeclampsia in pregnant women concluded that nifedipine 
is associated with greater effective control of blood pressure and 
prolongation of gestation, compared with other antihypertensive for 
women with severe preeclampsia [9]. 
A prospective study conducted in 2012 evaluated the effectiveness 
and safety of oral Labetalol and oral Nifedipine in pregnant women 
with Pregnancy induced hypertension (PIH) and concluded that 
labetalol is more effective than Nifedipine in controlling blood 
pressure whereas tachycardia (11 %) and occipital headache are 
more common with nifedipine [10]. Despite of various clinical trials 
conducted, there is seldom robustness in the treatment guidelines of 
preeclampsia. Therefore our study focuses on an assessment of 
safety and efficacy of oral labetalol and oral nifedipine in the control 
of hypertension in pregnancy. 
MATERIALS AND METHODS 
A Prospective Observational Study has been carried out on 
Comparison of Safety and Efficacy of oral Labetalol and oral 
Nifedipine in Pre-eclampsia patients in Obstetrics and Gynecology 
Department at Government General Hospital, Guntur for 6 months 
from 1st March 2014 to 31st August 2014. 
The study is completely inpatient based; primary data was 
generated by studying patients admitted for the management of 
preeclampsia. Inclusion Criteria is pregnant women of age between 
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15-40 y with preeclampsia with elevated systolic blood pressure of ≥ 
140 mmHg and diastolic blood pressure of ≥ 90 mmHg. Pregnant 
women with co-morbidities like Asthma/Obstructive Airway 
Disease and Heart Failure are excluded. 
A total number of 152 patients who were prescribed with either 
Labetalol or Nifedipine were selected and included in the study. On 
admission detailed patient case history was collected which includes 
the details like age, obstetric and gynaecological history, past 
medical history, medication history, blood pressure, socioeconomic 
status. Blood Pressure is recorded using mercury 
sphygmomanometer. After diagnosing preeclampsia, written 
informed consent is taken and the trial group was treated with 
either Labetalol or Nifedipine. 
Pregnant women receiving labetalol 100 mg twice daily are 
considered as group A and who are receiving Nifedipine 10 mg 
thrice a day (TID) are considered as group B. Dose was increased 
every 1-2 days if required, up to a maximum of Labetalol 2400 mg/d 
and Nifedipine 120 mg/d untill satisfactory Blood Pressure (BP) 
(≤120/80 mmHg) control was achieved. Average of three 
consecutive measurements is considered as Blood pressure (BP) 
reading and is monitored 4th hourly by sphygmomanometer. If 
blood pressure doesn’t decrease even after increasing the dose to 
maximum, additional antihypertensive agent is added and the 
treatment is considered as failure. 
Investigations Considered are complete hemogram, Liver function 
tests (LFT’s), Renal function tests (RFT’s), Serum uric acid, 
Fundoscopy, Ultrasound scan. Those patients with impending 
eclampsia were given Magnesium sulphate. Decision to continue 
with conservative management of pregnancy or to deliver and mode 
of delivery is made depending on maternal and fetal indications. 
Then patients were followed until delivery and the various modes of 
delivery were noted. The patients were interviewed for the drug 
adverse effects. Later consultation was made with the physician and 
the data were documented. Finally, the documented data was 
analyzed using Microsoft excel version and statistical methods (t 
test) to find p value to compare the two treatment groups. 
RESULTS 
A comparative study consisting of 152 pregnant women, 76 
pregnant women with preeclampsia treated with Labetalol(Group 
A) and 76 pregnant women with preeclampsia treated with 
Nifedipine(Group B) is undertaken to study the safety & efficacy of 
the drugs. Both the two groups had comparable demographics and 
their characteristics are represented in table 1. 
 
Table 1: Characteristics of pregnant women randomised to oral nifedipine or oral labetalol 
Characteristic (range) Labetalol Nifedipine 
Age Group (15-40 y) 24.23±3.64 23.6±4.28 
Primi’s 17 22 
Gravidity (1-3) 2 2 
Parity (0-3) 1 1 
Systolic Blood Pressure (130-210) 162.36±20.72 146.05±9.16 
Diastolic Blood Pressure (80-140) 105±12.46 95.26±6.87 
Pulse rate (80-105) 87.94±4.39 86.39±2.74 
Labetalol drug sample size-(n=76), Nifedipine sample size-(n=76), The Age wise distribution of pregnant women with Preeclampsia is as shown in fig. 1. 
 
 
Fig. 1: Age wise distribution of pregnant women with 
preeclampsia. In our study, we observed that 21–25 years aged 
pregnant women are more prominent with Preeclamspia 
followed by age group 15-20 y and 26-30 y 
 
Primi’s is more prone to pre-eclampsia than females with second 
and third gravidity and is as shown in fig. 2. 
On individual assessment of the adverse effects of Labetalol and 
Nifedipine, patients on labetalol has experienced side effects mostly 
Pedal edema (22%), Headache (20%), Sweating (10%), Orthostatic 
Hypotension (9%), Blurred vision (9%), Chills &Rigors (7%), Facial 
Edema (7%) etc and side effects observed mostly due to Nifedipine 
are Pedal edema (31%), Headache (17%), Sweating (10%), 
Orthostatic Hypotension (7%), Dizziness (7%), Cough (7%), Facial 
Edema (5%) etc. 
On comparison of common adverse effects of the both drugs, Labetalol 
and Nifedipine, we found Pedal edema (50%, 47.36%), Headache 
(28.94%, 26.31%), Sweating (23.68%, 15.78%), Orthostatic 
Hypotension (21.05%, 10.52%), Blurred Vision (21.05%, 2.63%), 
Chills and Rigors (15.78%, 7.89%), Facial Edema (15.78%, 7.89%), 
Dizziness (10.52%, 10.52%), Nausea & Vomiting (10.52%, 0), 
Bronchospasm (7.89%, 2.63%), Fever (7.89%, 5.26%) respectively. 
We found Labetalol (Group A) has experienced more adverse effects 
than Nifedipine and is as shown in fig. 3 and in table 2. 
 
 
Fig. 2: Risk based on obstetrics history 
 
Comparing the efficacy between labetalol and nifedipine is as shown 
in fig. 4, Duration of days required for Labetalol is 5 days (5±2.63 d), 
Nifedipine is 7.5 days (7.5±3.83 d) and Duration of Hours required 
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for Labetalol is 120 h (120±63.12) and 180 h for Nifedipine 
(180±91.92) with P value of 0.0015 and are as listed in table 3. 
There is significant difference between both the treatment groups. 
 
Fig. 3: Comparison of adverse effects of labetalol and nifedipine 
 
Fig. 4: Comparison of efficacy of labetalol and nifedipine 
 
Table 2: Comparison of adverse effects of oral labetalol and nifedipine 
Adverse effect Labetalol (n=76) Nifedipine (n=76) 
 No of Patients Percentage No of patients Percentage 
Pedal Edema 38 50 36 47.36 
Headache 22 28.94 20 26.31 
Sweating 18 23.68 12 15.78 
Orthostatic Hypotension 16 21.05 8 10.52 
Blurred Vision 16 21.05 2 2.63 
Chills & Rigors 12 15.78 6 7.89 
Facial Edema 12 15.78 6 7.89 
Dizziness 8 10.52 8 10.52 
Nausea & Vomiting 8 10.52 0 0 
Bronchospasm 6 7.89 2 2.63 
Fever 6 7.89 4 5.26 
Cough 0 0 8 10.52 
Anasarca 0 0 2 2.63 
Periorbital Edema 0 0 2 2.63 
*n-sample size 
 
Table 3: Comparision of efficacy of labetalol and nifedipine 
Drug name Labetalol (n=76) Nifedipine (n=76) 
Duration in days 5 7.5 
Duration in Hours 120 180 
mean±SD (d) 5±2.63 7.5±3.83 
mean±SD (h) 120±63.12 180±91.92 
P value: 0.0015 
 SD: Standard Deviation,*n-Sample Size. 
 
DISCUSSION 
The Cochrane review on drugs for the treatment of very high blood 
pressure in pregnancy concluded that until better evidence is 
available, the choice of antihypertensive should depend on the 
clinician’s experience and familiarity with a particular drug [11]. 
The appropriate selection of antihypertensive in pre-eclampsia is 
contraversial in the literature. Most commonly preferred choice of 
antihypertensive is Labetalol, Methyldopa, and Nifedipine in pre-
eclampsia [12]. 
As per the National Institute for Health and Clinical Excellence (NICE) 
guidelines for hypertension in pregnancy, the preferred choice of drug 
is oral Labetalol to oral nifedipine and Methyldopa [8]. 
Main findings 
In our study, we included 152 pregnant women with Group A(n=76), 
Group B(n=76). Group A is treated Labetalol and Group B with 
Nifedipine. Treatment Strategies are Labetalol 100 mg twice daily, 
Maximum Dosage 2400 mg/d; Nifedipine 10 mg Thrice a day (TID), 
Maximum Dosage 120 mg/d. If there is seldom improvement to 
normal dosage, the dosage was increased in increments to both 
treatment groups. Pregnant women were monitored for Blood 
Pressure every 4 h and adverse effects frequently. Based on the 
statistics, we observed that Labetalol is more effective than 
Nifedipine in controlling blood pressure whereas the safety concern, 
nifedipine has less frequency of side effects than labetalol. 
Strengths and Limitations 
The strengths of our study are the generalizability of results is due 
to the diversity of the study population from various regions and 
unbiased since there is no loss of data as it is a prospective study 
and there exists a chronological relationship between drug exposure 
and outcome. 
The limitations of our study are Study population is heterogenous 
which includes both proteinuric and non-proteinuric pregnant 
women with high blood pressure and Blood pressure considered is 
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the highest single reading recorded among all four hourly 
measurements for the entire day. 
Interpretation 
The results of our study are similar to that of a prospective, 
randomized, open labeled study, the use of oral labetalol with 
oral nifedipine in hypertensive urgencies in the emergency 
department of obstetrics conducted by McDonald AJ et al. The 
pretreatment Blood pressure for labetalol was 195/127 mmHg 
which decreased to 154/100 mmHg and of nifedipine was 
198/128 mm Hg, alleviated to 163/100 mm Hg (P>.2). No 
significant side effects occurred with either drug. Labetalol is 
effective when compared to nifedipine in pregnancy induced 
hypertensive emergencies [13]. 
However, they diverge from a Meta-analysis Study conducted by Liu 
QQ et al., the study includes the assessment of the efficacy, side 
effects and perinatal outcome of nifedipine compared with other 
antihypertensives.  
Compared with other antihypertensives, nifedipine contributed 
greater efficacy in controlling blood pressure (OR = 2.65, 95%CI: 
1.65-4.25, P<0.01) [9]. 
A recent prospective study conducted by Nita K. Patela et al. in 2012 
to evaluate the comparative effectiveness and safety of nifedipine, 
methyldopa and labetalol monotherapy in patients with Pregnancy 
induced hypertension (PIH) concluded that Labetalol was more 
effective than methyldopa and nifedipine in controlling blood 
pressure in patients with Pregnancy induced hypertension (PIH) 
providing sustenance for our study [10]. 
There was no major adverse event attributed to either drug 
regimens. Our data supports recent guidelines and expert opinion 
that oral labetalol is the suitable first-line antihypertensive for 
hypertensive emergencies of pregnancy. 
CONCLUSION 
From our study, we observed that Oral Labetalol is more efficacious 
than Oral Nifedipine, with an exception of more adverse effects and 
high cost. Hence most of the Health care professionals preferring 
Nifedipine to Labetalol. However, due to inter individual variation, 
prevalence of side effects may vary and due to their less severity, it’s 
better to opt labetalol for effective control of blood pressure in 
preeclampsia. 
Practical and research recommendations 
In order to have an appropriate therapeutic decision making, further 
studies should be performed in the future with large homogenous 
study population for better results. 
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